Strategy

Our Philosophy

Founded in 1992 in Houston, Texas, Fabre-Kramer Pharmaceuticals focuses on compounds to license-in, develop for global registration, and license-out to commercial partners. Fabre-Kramer then creates life-cycle management strategies to maximise the commercial potential of those compounds.

In-and-Out Licensing
Fabre-Kramer Pharmaceuticals forms partnerships with individual researchers, research institutions, pharmaceutical as well as biotechnology companies, to license in molecules for development and further license them out for commercialization.

FKP's main therapeutic areas of activity are psychiatry and neurology.

Project Management
Once a candidate is licensed-in, a dedicated, experienced, and multidisciplinary project management team is established to achieve a timely, market and regulatory driven pharmaceutical development to obtain marketing authorizations in major markets, i.e. North America, Europe and Japan.

Shared Objectives with Licensors
As Fabre-Kramer Pharmaceuticals does not conduct sales and marketing, only a rapid and successful registration, along with superior marketing guarantee the company’s return on investment, sustainability, and viability. Fabre-Kramer grants a fair share of downstream profits to the licensor.

Principal Partners
GlaxoSmithKline, Bristol-Myers Squibb, Organon, Wyeth, Grupo Ferrer, Axon, and Questcor Pharmaceuticals